Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma, Kaposi 4Leukemia, Lymphocytic, Chronic, B-Cell 2Epstein-Barr Virus Infections 2Cytomegalovirus Infections 2Acquired Immunodeficiency Syndrome 2Sarcoma 1Multi-centric Castleman's Disease 1Lymphoproliferative Disorders 1Lymphoma 1Leukemia 1Immune Reconstitution Inflammatory Syndrome 1Herpes Simplex 1Glioblastoma 1Fatigue Syndrome, Chronic 1Fatigue 1Castleman Disease 1

Interventions

Valganciclovir 1Therapeutic Touch 1TES 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Fatigue Syndrome, Chronic × Valganciclovir × Clear all
NCT00478465 2022-05-27

Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)

Stanford University

Phase 1/2 Completed
30 enrolled

Fatigue, Herpes Simplex, Fatigue Syndrome, Chronic, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡